Chemotherapy source book /

Chemotherapy source book /

Saved in:
Bibliographic Details
Edition:5th ed.
Imprint:Philadelphia : Wolters Kluwer Health/Lippincott Williams & Wilkins, ©2012.
Description:1 online resource (xiv, 833 pages) : illustrations
Language:English
Subject:
Cancer -- Chemotherapy.
Antineoplastic agents.
Antimitotic agents.
Neoplasms -- drug therapy
Antineoplastic Agents -- therapeutic use
Antineoplastic Agents
Antimitotic Agents
Antimitotic agents
Antineoplastic agents
Cancer -- Chemotherapy
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/13441418
Hidden Bibliographic Details
Varying Form of Title:Perry's the chemotherapy source book
Other authors / contributors:Perry, Michael C. (Michael Clinton), 1945-
Doll, Donald C.
Freter, Carl E.
ISBN:9781469874685
1469874687
9781469803432
1469803437
9781451101454
1451101457
Language / Script:Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.
Notes:Includes bibliographical references and index.
Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
Print version record.
Summary:Perry's The Chemotherapy Source Book, now in its fifth edition, provides information on the choice of chemotherapeutic agents, the use of combination chemotherapy, and the toxicity of individual drugs. Organized by site, this is the only book of its kind to focus strictly on the clinical practice of chemotherapy, and is meant to serve as a \u201cone-stop shop\u201d for information on choice of chemotherapeutic agents, treatment outlines, grading of side effects, and dose modification.
Other form:Chemotherapy source book. 5th ed. Philadelphia : Wolters Kluwer/Lippincott Williams & Wilkins, ©2012 9781451101454
Standard no.:40021000554
Table of Contents:
  • Scientific basis of cancer chemotherapy
  • Norton-Simon hypothesis
  • Drug resistance
  • Principles of chemotherapy
  • Clinical trials
  • Hematopoietic growth factors
  • Biologic response modifiers: principles of biotherapy
  • Intraventricular and intrathecal therapy
  • Intraperitoneal chemotherapy
  • Intraarterial chemotherapy
  • Hematopoietic stem cell transplantation
  • Oral toxicity
  • Dermatologic toxicity
  • Extravasation
  • Hypersensitivity reactions
  • Ocular side effects of cancer therapeutics
  • Cardiotoxicity of cancer therapy
  • Pulmonary toxicity of chemotherapeutic agents
  • Gastrointestinal complications of chemotherapy
  • Hepatotoxicity of chemotherapeutic agents
  • Chemotherapy-induced renal and electrolyte dysfunction
  • Chemotherapy-induced peripheral neuropathy
  • Vascular toxicity of antineoplastic agents
  • Second malignancies after chemotherapy
  • Chemotherapy in pregnancy
  • Gonadal complications and teratogenicity of cancer therapy
  • Central venous access for chemotherapy
  • Systemic therapy for advanced melanoma
  • Chemotherapy of primary brain tumors
  • Chemotherapy for head and neck cancer
  • Chemotherapy of lung cancer
  • Breast cancer
  • Gastrointestional cancer
  • Endocrine tumors
  • Chemotherapy of genitourinary cancer
  • Chemotherapy of gynecologic cancers
  • Chemotherapy of carcinoma of unknown primary site
  • Chemotherapy of bone and soft tissue sarcomas
  • Chemotherapy for pediatric solid tumors
  • Chemotherapy for childhood leukemia
  • Chemotherapy of Hodgkin lymphoma
  • Non-Hodgkin lymphoma
  • Chronic lymphocytic leukemia
  • Acute myeloid leukemia
  • Myelodysplastic syndromes
  • Management of myeloproliferative disorders and chronic myeloid leukemia
  • Chemotherapy of multiple myeloma
  • Appendics: I: Chemotherapeutic agents
  • II: Chemotherapy programs
  • III: Common terminology criteria for adverse events (CTCAE) version 4.0.

Similar Items